We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Subgroup Analysis in the Steroids for Corneal Ulcers Trial—Reply

Muthiah Srinivasan, MD; Jeena Mascarenhas, MD; Revathi Rajaraman, MD; Meenakshi Ravindran, MD; David Glidden, PhD; Catherine E. Oldenburg, MPH; John P. Whitcher, MD; Michael E. Zegans, MD; Stephen D. McLeod, MD; Thomas M. Lietman, MD; Nisha R. Acharya, MD, MS; for the Steroids for Corneal Ulcers Trial Group
Arch Ophthalmol. 2012;130(6):807-808. doi:10.1001/archophthalmol.2012.352.
Text Size: A A A
Published online


In reply

Dulku raises an important point and one that we fully agree with. A clinical trial has 1 primary outcome; all other analyses are either secondary prespecified or post hoc exploratory analyses and should be noted as such.

In our study, the subgroup analysis assessing the effect of corticosteroids in severe bacterial ulcers was prespecified prior to any of the results being available, so the cut points chosen for the subgroups were decided a priori based on clinical interest. We made an attempt to limit the number of subgroup analyses in an effort to reduce the chances of making a type I error. It is still possible that our finding that steroids are of benefit in patients with ulcers of greater severity is not true. However, the fact that this finding was corroborated across various subgroups representing different ways of measuring severity such as worse visual acuity, central location of the ulcer, deeper ulcer, and larger infiltrate increases the credibility of our finding. We completely agree that this result, along with any others that we subsequently find, will need to be confirmed in future randomized trials.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





June 1, 2012
Simon Dulku, MA, FRCOphth
Arch Ophthalmol. 2012;130(6):807-808. doi:10.1001/archophthalmol.2011.1919.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...